SEC Info - Arcadia Biosciences, Inc.

SEC Info℠

Home

Help

Please Sign In

Arcadia Biosciences, Inc. – ‘8-K’ for 3/28/24

On: Thursday, 3/28/24, at 5:02pm ET · For: 3/28/24 · Accession #: 950170-24-38153 · File #: 1-37383

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/28/24  Arcadia Biosciences, Inc.         8-K:2,9     3/28/24   10:565K                                   Donnelley … Solutions/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     41K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     59K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML    331K 
 5: R1          Document And Entity Information                     HTML     47K 
 7: XML         IDEA XML File -- Filing Summary                      XML     11K 
10: XML         XBRL Instance -- rkda-20240328_htm                   XML     15K 
 6: EXCEL       IDEA Workbook of Financial Report Info              XLSX      8K 
 4: EX-101.SCH  XBRL Taxonomy Extension Schema With Embedded         XSD     72K 
                Linkbases Document -- rkda-20240328                              
 8: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    18K 
 9: ZIP         XBRL Zipped Folder -- 0000950170-24-038153-xbrl      Zip     32K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

8-K

i false i 000146944300014694432024-03-282024-03-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 28, 2024

i Arcadia Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)


i Delaware	i 001-37383	i 81-0571538
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 5950 Sherry Lane i Suite 215
i Dallas, i Texas		i 75225
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: i 214 i 974-8921

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common	i RKDA	i The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On March 28, 2024 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1, and the Company's annual financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference.

The information furnished in this Form 8-K, the press release attached as Exhibit 99.1, and the financial information attached as Exhibit 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02, in the press release attached as Exhibit 99.1, and in the financial information attached as Exhibit 99.2, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.		Description

99.1		Arcadia Biosciences Announces Fourth-Quarter and Full Year 2023 Financial Results and Business Highlights
99.2		Arcadia Biosciences Full Year 2023 Financial Information
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


			ARCADIA BIOSCIENCES, INC.

Date:	March 28, 2024	By:	/s/ *THOMAS J. SCHAEFER*
			Thomas J. Schaefer, Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	3/28/24	None on these Dates
	12/31/23
		List all Filings

↑Top

Filing Submission 0000950170-24-038153 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)